The pharma sector is often called India’s “sunrise industry” – it not only meets domestic healthcare needs but also supplies medicines to the world. For investors, this sector has delivered resilience during crises (like Covid-19) and continues to show strong long-term growth potential.

That’s where Pharma Mutual Funds come in. These are sectoral funds that invest in pharmaceutical, healthcare, and allied companies, giving you exposure to one of India’s most promising industries.
But are they right for your Portfolio? Let’s explore.
Pharma Mutual Funds are sectoral Equity Funds that invest primarily in companies from:
Since they are sector-specific, they carry higher risk than Diversified Funds, but also offer the chance to capture outsized gains when the sector outperforms.
Here’s why the Indian pharma industry is considered a strong bet:
In short: Pharma funds allow you to benefit from both domestic consumption growth and global demand for cost-effective drugs.
Talk to our investment specialist
Fund Selection Methodology used to find 10 funds
Fund NAV Net Assets (Cr) 3 MO (%) 6 MO (%) 1 YR (%) 3 YR (%) 5 YR (%) 2025 (%) TATA India Pharma & Healthcare Fund Growth ₹32.9703
↑ 0.19 ₹1,387 14 9.4 8.6 21.6 13.5 -4.9 Nippon India Pharma Fund Growth ₹562.294
↑ 1.92 ₹8,636 13 10.2 9.2 21 12.8 -3.3 UTI Healthcare Fund Growth ₹330.241
↑ 1.85 ₹1,217 17.9 17.1 15 26 14.6 -3.1 SBI Healthcare Opportunities Fund Growth ₹496.754
↑ 7.59 ₹4,566 18.4 17.9 14.2 24.2 16.4 -3.5 Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 10 Jul 26 Research Highlights & Commentary of 4 Funds showcased
Commentary TATA India Pharma & Healthcare Fund Nippon India Pharma Fund UTI Healthcare Fund SBI Healthcare Opportunities Fund Point 1 Lower mid AUM (₹1,387 Cr). Highest AUM (₹8,636 Cr). Bottom quartile AUM (₹1,217 Cr). Upper mid AUM (₹4,566 Cr). Point 2 Established history (10+ yrs). Established history (22+ yrs). Oldest track record among peers (27 yrs). Established history (21+ yrs). Point 3 Not Rated. Top rated. Rating: 1★ (lower mid). Rating: 2★ (upper mid). Point 4 Risk profile: High. Risk profile: High. Risk profile: High. Risk profile: High. Point 5 5Y return: 13.46% (lower mid). 5Y return: 12.79% (bottom quartile). 5Y return: 14.56% (upper mid). 5Y return: 16.38% (top quartile). Point 6 3Y return: 21.58% (lower mid). 3Y return: 20.97% (bottom quartile). 3Y return: 25.99% (top quartile). 3Y return: 24.17% (upper mid). Point 7 1Y return: 8.55% (bottom quartile). 1Y return: 9.18% (lower mid). 1Y return: 14.95% (top quartile). 1Y return: 14.24% (upper mid). Point 8 Alpha: -7.02 (bottom quartile). Alpha: -3.90 (lower mid). Alpha: 0.91 (top quartile). Alpha: -0.04 (upper mid). Point 9 Sharpe: 0.14 (lower mid). Sharpe: 0.07 (bottom quartile). Sharpe: 0.42 (top quartile). Sharpe: 0.36 (upper mid). Point 10 Information ratio: -0.62 (lower mid). Information ratio: -0.93 (bottom quartile). Information ratio: 0.08 (top quartile). Information ratio: -0.40 (upper mid). TATA India Pharma & Healthcare Fund
Nippon India Pharma Fund
UTI Healthcare Fund
SBI Healthcare Opportunities Fund
All the funds mentioned above are ideal, we are giving you detailed analysis of 3 funds.
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. Research Highlights for TATA India Pharma & Healthcare Fund Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Research Highlights for Nippon India Pharma Fund Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on (Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. Research Highlights for UTI Healthcare Fund Below is the key information for UTI Healthcare Fund Returns up to 1 year are on (Erstwhile SBI Pharma Fund) To provide the investors maximum growth opportunity through equity
investments in stocks of growth oriented sectors of the economy. Research Highlights for SBI Healthcare Opportunities Fund Below is the key information for SBI Healthcare Opportunities Fund Returns up to 1 year are on 1. TATA India Pharma & Healthcare Fund
TATA India Pharma & Healthcare Fund
Growth Launch Date 28 Dec 15 NAV (10 Jul 26) ₹32.9703 ↑ 0.19 (0.56 %) Net Assets (Cr) ₹1,387 on 31 May 26 Category Equity - Sectoral AMC Tata Asset Management Limited Rating Risk High Expense Ratio 2.17 Sharpe Ratio 0.14 Information Ratio -0.62 Alpha Ratio -7.02 Min Investment 5,000 Min SIP Investment 150 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Jun 21 ₹10,000 30 Jun 22 ₹8,951 30 Jun 23 ₹10,628 30 Jun 24 ₹15,238 30 Jun 25 ₹17,550 30 Jun 26 ₹18,791 Returns for TATA India Pharma & Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 10 Jul 26 Duration Returns 1 Month 5.4% 3 Month 14% 6 Month 9.4% 1 Year 8.6% 3 Year 21.6% 5 Year 13.5% 10 Year 15 Year Since launch 12% Historical performance (Yearly) on absolute basis
Year Returns 2025 -4.9% 2024 40.4% 2023 36.6% 2022 -8% 2021 19.1% 2020 64.4% 2019 5.5% 2018 -2.6% 2017 4.7% 2016 -14.7% Fund Manager information for TATA India Pharma & Healthcare Fund
Name Since Tenure Rajat Srivastava 16 Sep 24 1.79 Yr. Data below for TATA India Pharma & Healthcare Fund as on 31 May 26
Equity Sector Allocation
Sector Value Health Care 93.6% Basic Materials 3.96% Consumer Defensive 1.35% Financial Services 0.4% Asset Allocation
Asset Class Value Cash 0.7% Equity 99.3% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMA9% ₹130 Cr 723,130 HealthCare Global Enterprises Ltd (Healthcare)
Equity, Since 31 Dec 18 | HCG6% ₹81 Cr 1,276,727
↑ 15,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB6% ₹80 Cr 120,600 Abbott India Ltd (Healthcare)
Equity, Since 30 Sep 25 | ABBOTINDIA5% ₹75 Cr 27,953 Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | CIPLA5% ₹72 Cr 512,754 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Jul 25 | MAXHEALTH5% ₹67 Cr 690,488 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSP5% ₹63 Cr 77,345
↑ 6,861 Rainbow Childrens Medicare Ltd (Healthcare)
Equity, Since 31 Jul 25 | 5435245% ₹63 Cr 454,338
↑ 7,205 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | DRREDDY4% ₹56 Cr 428,116
↑ 54,652 Mankind Pharma Ltd (Healthcare)
Equity, Since 30 Apr 23 | MANKIND4% ₹52 Cr 220,018 2. Nippon India Pharma Fund
Nippon India Pharma Fund
Growth Launch Date 5 Jun 04 NAV (10 Jul 26) ₹562.294 ↑ 1.92 (0.34 %) Net Assets (Cr) ₹8,636 on 31 May 26 Category Equity - Sectoral AMC Nippon Life Asset Management Ltd. Rating ☆☆ Risk High Expense Ratio 1.81 Sharpe Ratio 0.07 Information Ratio -0.93 Alpha Ratio -3.9 Min Investment 5,000 Min SIP Investment 100 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Jun 21 ₹10,000 30 Jun 22 ₹8,540 30 Jun 23 ₹10,376 30 Jun 24 ₹14,608 30 Jun 25 ₹16,993 30 Jun 26 ₹18,254 Returns for Nippon India Pharma Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 10 Jul 26 Duration Returns 1 Month 5.1% 3 Month 13% 6 Month 10.2% 1 Year 9.2% 3 Year 21% 5 Year 12.8% 10 Year 15 Year Since launch 20% Historical performance (Yearly) on absolute basis
Year Returns 2025 -3.3% 2024 34% 2023 39.2% 2022 -9.9% 2021 23.9% 2020 66.4% 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% Fund Manager information for Nippon India Pharma Fund
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 21.26 Yr. Kinjal Desai 25 May 18 8.11 Yr. Amber Singhania 11 Mar 26 0.31 Yr. Data below for Nippon India Pharma Fund as on 31 May 26
Equity Sector Allocation
Sector Value Health Care 97.92% Asset Allocation
Asset Class Value Cash 2.08% Equity 97.92% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA13% ₹1,153 Cr 6,406,349 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | LUPIN7% ₹631 Cr 2,783,991
↓ -100,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY7% ₹580 Cr 4,449,746 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | CIPLA6% ₹532 Cr 3,795,054
↑ 300,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB6% ₹501 Cr 750,754
↓ -100,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP5% ₹449 Cr 548,795 Mankind Pharma Ltd (Healthcare)
Equity, Since 30 Apr 23 | MANKIND4% ₹340 Cr 1,431,195
↑ 300,000 Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | MEDPLUS4% ₹317 Cr 3,545,229
↓ -82,048 Sai Life Sciences Ltd (Healthcare)
Equity, Since 31 Dec 24 | SAILIFE3% ₹296 Cr 2,555,745 Ajanta Pharma Ltd (Healthcare)
Equity, Since 30 Apr 22 | AJANTPHARM3% ₹277 Cr 946,323 3. UTI Healthcare Fund
UTI Healthcare Fund
Growth Launch Date 28 Jun 99 NAV (10 Jul 26) ₹330.241 ↑ 1.85 (0.56 %) Net Assets (Cr) ₹1,217 on 31 May 26 Category Equity - Sectoral AMC UTI Asset Management Company Ltd Rating ☆ Risk High Expense Ratio 2.26 Sharpe Ratio 0.42 Information Ratio 0.08 Alpha Ratio 0.91 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Jun 21 ₹10,000 30 Jun 22 ₹8,478 30 Jun 23 ₹10,006 30 Jun 24 ₹14,264 30 Jun 25 ₹17,337 30 Jun 26 ₹19,764 Returns for UTI Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 10 Jul 26 Duration Returns 1 Month 6.5% 3 Month 17.9% 6 Month 17.1% 1 Year 15% 3 Year 26% 5 Year 14.6% 10 Year 15 Year Since launch 15% Historical performance (Yearly) on absolute basis
Year Returns 2025 -3.1% 2024 42.9% 2023 38.2% 2022 -12.3% 2021 19.1% 2020 67.4% 2019 1.2% 2018 -7.5% 2017 6.2% 2016 -9.7% Fund Manager information for UTI Healthcare Fund
Name Since Tenure Kamal Gada 2 May 22 4.17 Yr. Data below for UTI Healthcare Fund as on 31 May 26
Equity Sector Allocation
Sector Value Health Care 94.45% Asset Allocation
Asset Class Value Cash 5.55% Equity 94.45% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA9% ₹108 Cr 600,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB5% ₹59 Cr 88,814
↑ 28,076 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | AJANTPHARM5% ₹57 Cr 195,295
↓ -41,216 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND4% ₹48 Cr 215,251 Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | LUPIN4% ₹46 Cr 203,834
↓ -6,166 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP4% ₹43 Cr 53,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDY3% ₹38 Cr 290,000 Caplin Point Laboratories Ltd (Healthcare)
Equity, Since 31 Dec 23 | CAPLIPOINT3% ₹37 Cr 185,000
↑ 39,847 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEM3% ₹37 Cr 68,000 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | FORTIS3% ₹37 Cr 400,000 4. SBI Healthcare Opportunities Fund
SBI Healthcare Opportunities Fund
Growth Launch Date 31 Dec 04 NAV (09 Jul 26) ₹496.754 ↑ 7.59 (1.55 %) Net Assets (Cr) ₹4,566 on 31 May 26 Category Equity - Sectoral AMC SBI Funds Management Private Limited Rating ☆☆ Risk High Expense Ratio 1.97 Sharpe Ratio 0.36 Information Ratio -0.4 Alpha Ratio -0.04 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-15 Days (0.5%),15 Days and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Jun 21 ₹10,000 30 Jun 22 ₹8,662 30 Jun 23 ₹11,165 30 Jun 24 ₹15,491 30 Jun 25 ₹18,739 30 Jun 26 ₹21,357 Returns for SBI Healthcare Opportunities Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 10 Jul 26 Duration Returns 1 Month 5.8% 3 Month 18.4% 6 Month 17.9% 1 Year 14.2% 3 Year 24.2% 5 Year 16.4% 10 Year 15 Year Since launch 15.6% Historical performance (Yearly) on absolute basis
Year Returns 2025 -3.5% 2024 42.2% 2023 38.2% 2022 -6% 2021 20.1% 2020 65.8% 2019 -0.5% 2018 -9.9% 2017 2.1% 2016 -14% Fund Manager information for SBI Healthcare Opportunities Fund
Name Since Tenure Tanmaya Desai 1 Jun 11 15.09 Yr. Data below for SBI Healthcare Opportunities Fund as on 31 May 26
Equity Sector Allocation
Sector Value Health Care 88.67% Basic Materials 8.82% Asset Allocation
Asset Class Value Cash 2.45% Equity 97.49% Debt 0.06% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA11% ₹504 Cr 2,800,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB7% ₹300 Cr 450,000 Acutaas Chemicals Ltd (Basic Materials)
Equity, Since 30 Jun 24 | 5433496% ₹282 Cr 900,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Jan 26 | APOLLOHOSP5% ₹245 Cr 300,000 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH5% ₹217 Cr 2,250,000 Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Mar 26 | AUROPHARMA4% ₹178 Cr 1,250,000
↑ 250,000 Aster DM Healthcare Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 24 | ASTERDM4% ₹175 Cr 2,400,000 Laurus Labs Ltd (Healthcare)
Equity, Since 31 Aug 23 | LAURUSLABS4% ₹163 Cr 1,200,000 Biocon Ltd (Healthcare)
Equity, Since 30 Nov 24 | BIOCON4% ₹161 Cr 3,750,000 Torrent Pharmaceuticals Ltd (Healthcare)
Equity, Since 30 Jun 21 | TORNTPHARM3% ₹159 Cr 360,000
Pharma Mutual Funds generally track or take cues from the Nifty Pharma Index.
Key Highlights:
To more about index can be read on official website Nifty Pharma Index Document
Pharma funds are not for everyone. They are suitable if you are:
Not suitable for:
Here’s what most articles miss, but you should keep in mind:
Globally, populations are ageing, particularly in developed countries. Indian companies are well-placed to serve this demand.
Pharma is no longer just about medicines. Healthcare funds now capture hospitals, diagnostics, and preventive care businesses – expanding growth scope.
One USFDA ban can wipe out a stock’s value overnight. That’s why pharma funds spread risk across multiple companies.
The pandemic proved how pharma can outperform when healthcare demand spikes – but it also showed the need to stay cautious about hype-driven rallies.
Open Free Investment Account for Lifetime at Fincash.com.
Complete your Registration and KYC Process
Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest!
India’s healthcare system is unique — while public hospitals account for only 30% of total hospital beds, the rest come from the private sector. This means the majority of patients depend on private care, which directly drives higher demand for medicines, diagnostics, and health insurance.
For pharma investors, this is critical. Unlike other industries, demand here is not cyclical — healthcare is a necessity. The more patients turn to private care, the more they rely on affordable medicines, making pharmaceutical companies long-term revenue generators.
The imbalance also highlights another important point: out-of-pocket expenditure in India is one of the highest in the world, around 48–50% of total healthcare spend. This forces households to prioritise low-cost drugs, generic medicines, and insurance-backed treatments — exactly the segments where Indian pharma companies have a competitive advantage.
Add to this the rise of medical tourism (expected to reach $13 billion+ by 2026), demand for speciality care in tier-2 cities, and a growing middle class that spends more on preventive healthcare. All of these trends ensure steady tailwinds for pharma companies and, by extension, pharma mutual funds.
This trend explains why pharma mutual funds are seen as a defensive bet — they combine healthcare demand certainty with the growth potential of India’s expanding private medical sector. In other words, the gap between public and private healthcare isn’t just a social challenge — it’s an investment signal, and one that smart investors can capture through pharma-focused fund.
Pharma Mutual Funds give investors a chance to tap into one of India’s strongest industries – with global leadership in generics, a growing domestic market, and government support. However, these are high-risk, high-reward funds. Don’t allocate more than 10–15% of your portfolio to sectoral funds, and always combine them with diversified mutual funds for stability.
If you believe in the long-term growth of healthcare and India’s role as the “Pharmacy of the World,” pharma funds can be a smart addition to your portfolio.
A: Yes, since they are concentrated sector funds. Suitable only for those who can take high risk.
A: Diversified funds spread risk across sectors, pharma funds focus only on one. They can outperform in pharma bull runs but underperform otherwise.
A: At least 5 years. Short-term Investing in sector funds is not recommended.
A: Yes, SIPs help average out volatility in sectoral funds.
Please send list of funds which has the option of changing the sector of funds so that overall performance of mutual funds are always very good. Thanks and Regards
Are largecap is best investment on longterm